FRMM
ETHZilla Corporation
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$5.31
−4.15%Income statement
| Metric | TTM | 2025 |
|---|---|---|
| Revenue | ||
| Total Revenue | 10.8M | 6.5M |
| Cost of Revenue | 1.9M | — |
| Gross Profit | 8.9M | 6.5M |
| Operating Expenses | ||
| R&D Expense | — | — |
| SG&A Expense | 253.5M | 240.0M |
| General & Admin Expense | 244.1M | 240.0M |
| Selling & Marketing Expense | — | — |
| Other Expenses | 10.2M | — |
| Total Operating Expenses | 263.8M | 240.0M |
| Cost and Expenses | 265.7M | 240.0M |
| Operating Income (EBIT) | (254.9M) | (233.4M) |
| Non-Operating | ||
| Interest Income | 4.6M | 4.5M |
| Interest Expense | 4.3M | 3.1M |
| Net Interest Income | 342.1K | 1.5M |
| Other Non-Op Income/Expense | (275.3M) | (210.1M) |
| Non-Operating Income (excl Interest) | 268.7M | 207.0M |
| EBT (Pre-Tax Income) | (530.1M) | (443.5M) |
| Income Tax Expense | — | — |
| Bottom Line | ||
| Net Income | (527.4M) | (450.5M) |
| Earnings from Cont. Ops | (530.1M) | (443.5M) |
| Earnings from Discont. Ops | 2.7M | (7.0M) |
| Bottom Line Net Income | (527.4M) | (450.5M) |
| Per Share | ||
| Basic EPS | ($33.17) | ($55.18) |
| Diluted EPS | ($33.17) | ($55.18) |
| Revenue Per Share | $0.63 | $0.80 |
| Shares | ||
| Basic Shares Outstanding | 17.1M | 8.2M |
| Diluted Shares Outstanding | 17.1M | 8.2M |
| Profitability Metrics | ||
| EBITDA | (522.2M) | (440.5M) |
| D&A | 1.4M | — |
| EBIT | (523.6M) | (440.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026